Biopromic AB announced a technology co-development and license agreement with The Global Good Fund, managed by Intellectual Ventures, to develop a rapid, low-cost and high-sensitivity diagnostic test for the detection of tuberculosis (TB), one of the leading causes of death worldwide. The partnership will combine Global Good’s assay platform with Biopromic’s proprietary technologies in sample preparation and high-sensitivity antibodies to improve the accessibility of accurate TB testing in low- and middle-income countries.
Biopromic specializes in development of:
Rapid immunoassays for infectious disease detection
Ultrasensitive monoclonal antibodies
Production of antigens and reagents for human and veterinarian diagnostics